ACE inhibitors and angiotensin receptor blockers (ARBs) remain the first choice for most people with chronic kidney disease (CKD) and high blood pressure, because they do more than lower blood pressure: they reduce the pressure inside the kidney’s filtering units and slow the leak of protein into urine, both of which protect kidney function over time. But “best” depends heavily on the stage of kidney disease, whether diabetes is involved, potassium levels, and which other drugs are already on board. A growing roster of newer medications, particularly SGLT2 inhibitors and finerenone, has reshaped how doctors layer treatments to get the most kidney protection possible.
Why ACE Inhibitors and ARBs Are the Starting Point
The kidneys filter blood through tiny clusters of capillaries called glomeruli. When blood pressure is high, the pressure inside those capillaries rises too, gradually damaging the filter and allowing protein to spill into urine. ACE inhibitors (like lisinopril or ramipril) and ARBs (like losartan or telmisartan) target that problem directly. They relax the blood vessel leaving each glomerulus, which lowers the pressure inside the filter itself, independent of what happens to your overall blood pressure reading.1PubMed Central. ACE Inhibitors and ARBs in Chronic Kidney Disease: A Systematic Review of Randomized Controlled Trials on Albuminuria Reduction, eGFR Decline, and Safety That dual action, lowering systemic blood pressure and selectively protecting the kidney filter, is what makes these drugs the backbone of CKD treatment rather than just another way to bring numbers down on a cuff.
One important detail: high salt intake can blunt much of this benefit. In patients with CKD who ate more than about 14 grams of salt per day, the protein-lowering effect of ACE inhibitors was significantly weakened, and the risk of progressing to end-stage kidney disease went up, even when blood pressure looked similar across groups.2PubMed Central. Sodium intake, ACE inhibition, and progression to ESRD ARBs show the same pattern: the biggest reductions in protein leakage and blood pressure happen in people who keep sodium moderate.3Kidney International. Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers So the drug choice matters, but diet can quietly undermine or amplify whatever the drug is doing.
The Creatinine Bump You Shouldn’t Panic About
A common source of alarm: you start an ACE inhibitor or ARB, get blood work a week or two later, and your creatinine has gone up. That looks like the drug is hurting your kidneys. Usually it is not. Because these drugs lower the pressure inside the glomerulus, the filtration rate dips slightly at first, which shows up as a bump in creatinine. A rise of up to about 30 percent above baseline in the first two weeks is considered acceptable and typically stabilizes within two to four weeks.4Archives of Internal Medicine. Angiotensin-Converting Enzyme Inhibitor–Associated Elevations in Serum Creatinine: Is This a Cause for Concern? Patients who show this early bump actually tend to have better long-term kidney outcomes, because it signals the drug is doing its job of reducing glomerular pressure. A creatinine rise greater than 30 percent, or one that keeps climbing after a month, is a different story and warrants investigation for other problems like renal artery narrowing.
SGLT2 Inhibitors Changed the Landscape
Originally developed to lower blood sugar in type 2 diabetes, SGLT2 inhibitors (dapagliflozin, empagliflozin, canagliflozin, and others) turned out to have striking kidney-protective effects that go well beyond glucose control. Trials showed they slow the decline in kidney filtration, reduce the onset and progression of protein in the urine, and lower the risk of end-stage kidney disease and cardiovascular events.5PubMed. SGLT2 inhibitors use in kidney disease: what did we learn? These benefits hold up even in people without diabetes, suggesting the kidney protection comes from mechanisms other than just lowering blood sugar.6PubMed Central. Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease
SGLT2 inhibitors also modestly lower blood pressure, typically by a few points systolic, through mild fluid and sodium removal.7PubMed Central. The Effects of SGLT2 Inhibitors on Blood Pressure and Other Cardiometabolic Risk Factors That effect is welcome, but it is the kidney-specific protection that makes them so valuable. Current guidelines now recommend adding an SGLT2 inhibitor on top of an ACE inhibitor or ARB for most CKD patients, particularly those with diabetes or significant proteinuria, rather than choosing one or the other. Like ACE inhibitors, SGLT2 inhibitors cause a small early dip in filtration rate that can raise creatinine slightly. Again, this is expected and generally not a reason to stop the drug.
Finerenone for Diabetic Kidney Disease
Finerenone is a newer type of mineralocorticoid receptor antagonist, different from older drugs like spironolactone. In a large trial of patients with CKD and type 2 diabetes who were already taking an ACE inhibitor or ARB, finerenone reduced the risk of kidney disease progression by about 18 percent compared with placebo and also cut cardiovascular events.8PubMed. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes It lowered blood pressure too, with 24-hour systolic readings dropping roughly 8 to 11 points more than placebo depending on the dose.9PubMed Central. Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes But the kidney benefit was mostly independent of the blood pressure drop; analysis showed that only about 13 to 14 percent of finerenone’s effect on kidney and cardiovascular outcomes could be attributed to the change in blood pressure itself.10PubMed Central. Blood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes
The main watch-out with finerenone is potassium. Around 2.3 percent of trial participants on finerenone had to stop the drug because of high potassium, roughly double the rate in the placebo group.8PubMed. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes This is manageable with monitoring and, increasingly, with newer potassium-binding medications that can keep levels in check while you continue the kidney-protective drug.11Kidney Medicine. Which Blood Pressure Medicine Is Best for Kidney Disease?
Why You Should Never Combine an ACE Inhibitor With an ARB
If one drug blocking the renin-angiotensin system is good, wouldn’t two be better? Doctors tested that idea, and the answer was firmly no. The large ONTARGET trial found that combining an ACE inhibitor with an ARB did not reduce cardiovascular events compared with using either drug alone, but it doubled the rate of a combined outcome that included death, long-term dialysis, or doubling of creatinine. When just death or dialysis was counted, the combination tripled the risk.12PubMed Central. Combining Angiotensin Receptor Blockers With ACE Inhibitors in Elderly Patients The combination also raised the rate of dangerous hyperkalemia. Guidelines now strongly discourage dual RAAS blockade for CKD management in almost all circumstances.13PubMed. Renin Angiotensin Aldosterone System Blockade: Little to No Rationale for ACE Inhibitor and ARB Combinations
This is worth knowing because some patients, especially those with heavy proteinuria, may come across outdated information suggesting dual blockade could help. The evidence is clear enough now that the combination of an ACE inhibitor plus an ARB should be viewed as a genuinely dangerous pairing rather than an aggressive-but-reasonable strategy. Adding an SGLT2 inhibitor or finerenone on top of a single ACE inhibitor or ARB is the modern way to stack kidney protection without the risks of dual RAAS blockade.
Calcium Channel Blockers and an Underappreciated Risk
Calcium channel blockers (CCBs), particularly the dihydropyridine type like amlodipine and nifedipine, are among the most commonly prescribed blood pressure drugs. They work well for lowering blood pressure, and they are safe for the kidneys in the sense that they do not cause the potassium or creatinine concerns that RAAS blockers do. But there is an important nuance. Dihydropyridine CCBs dilate the blood vessel entering the glomerulus without equally dilating the one leaving it. That can actually increase the pressure inside the kidney’s filter, which is the opposite of what ACE inhibitors and ARBs do.
A recent real-world study of patients with type 2 diabetes who were already on a RAAS blocker and an SGLT2 inhibitor found that adding a dihydropyridine CCB was associated with roughly a third higher risk of adverse kidney outcomes compared with not adding one.14Kidney Medicine. Dihydropyridine Calcium Channel Blocker Therapy and Risk of CKD Progression in Type 2 Diabetes Treated With Renin Angiotensin System Inhibitors and SGLT2 Inhibitors: A Real-World Retrospective Cohort Study This does not mean CCBs should be avoided entirely in CKD. Sometimes you need additional blood pressure lowering and a CCB is the practical choice. But it does suggest that if your doctor is picking among several possible add-on drugs and your main concern is kidney protection, a CCB may not be the ideal third agent.
Diuretics in Advanced Kidney Disease
There is a persistent myth that thiazide diuretics stop working when kidney function drops below a certain point. For many years, doctors were taught to switch patients to loop diuretics once the estimated filtration rate fell below roughly 30. That thinking has been challenged. A randomized trial tested chlorthalidone, a thiazide-type diuretic, in patients whose kidney function averaged about 23, well into stage 4 CKD. Most were already taking an average of three or four blood pressure drugs, and over half were on a loop diuretic. Adding chlorthalidone dropped 24-hour systolic blood pressure by about 11 points more than placebo, a substantial effect on top of an already-complex drug regimen.15PubMed Central. Chlorthalidone for Hypertension in Advanced Chronic Kidney Disease
Beyond the blood pressure drop, chlorthalidone also reduced albuminuria by about 50 percent more than placebo and lowered a marker of heart stress called NT-proBNP.16Clinical Kidney Journal. Thiazide diuretics are back in CKD: the case of chlorthalidone Diuretics do not have the same direct glomerular protection that ACE inhibitors or SGLT2 inhibitors offer, but in advanced CKD where fluid overload and resistant hypertension are common, they can be an important layer. The main trade-off is electrolyte monitoring: thiazides can lower sodium and potassium, though in CKD patients already prone to high potassium from RAAS blockers, the potassium-lowering effect is sometimes actually helpful.
Blood Pressure Targets in CKD
Picking the right drug matters, but so does knowing how low to push the numbers. For people with CKD and significant proteinuria, aiming for a lower blood pressure target appears to slow kidney disease progression. Long-term follow-up from the Modification of Diet in Renal Disease study found that patients assigned to a lower blood pressure target had about a 32 percent lower risk of kidney failure compared with those assigned to a standard target.17PubMed. The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study
The picture is more complicated for people without heavy proteinuria. A meta-analysis of intensive versus standard blood pressure control in non-diabetic CKD patients found no significant difference in the rate of kidney function decline, the risk of reaching end-stage disease, or mortality in the main analysis. A signal for reduced death appeared only when the analysis was restricted strictly to patients without diabetes, and the benefit was more evident among those who had higher levels of proteinuria to begin with.18PubMed Central. Association of Intensive Blood Pressure Control and Kidney Disease Progression in Nondiabetic Patients With Chronic Kidney Disease: A Systematic Review and Meta-analysis The practical takeaway: if your urine shows significant protein, tighter blood pressure control is probably worth the effort and any side effects that come with additional medication. If protein levels are minimal, pushing to very low targets may not help the kidneys much and can increase the risk of lightheadedness, falls, and other issues from excessively low pressure.
Proteinuria as a Treatment Target in Its Own Right
Proteinuria is not just a marker that kidney disease exists; it is a driver of ongoing damage. Reducing protein in the urine is one of the most reliable ways to slow progression. In modeling from patients with IgA nephropathy, a treatment effect that reduced proteinuria by about 40 percent predicted a 59 percent lower risk of kidney failure or death, which translated to an estimated 6 extra years before reaching kidney failure. A 50 percent reduction in proteinuria predicted roughly 8.5 additional years.19Nephrology Dialysis Transplantation. #4503 ESTIMATING DELAY IN TIME TO KIDNEY FAILURE OR DEATH FOR TREATMENT EFFECTS ON PROTEINURIA IN IGA NEPHROPATHY Those numbers are from one specific kidney disease, so the exact years cannot be applied across the board. But the principle holds broadly: whatever blood pressure drug you are on, its effect on proteinuria is a meaningful signal of whether it is protecting the kidney, not just lowering a number on the cuff.
This is part of why ACE inhibitors, ARBs, SGLT2 inhibitors, and finerenone are favored over drugs like amlodipine or beta-blockers for kidney protection. The first group consistently reduces proteinuria; the second group lowers blood pressure without reliably lowering protein leakage.
Managing Blood Pressure on Dialysis
Once kidney disease reaches the point of dialysis, the rules shift. Blood pressure in dialysis patients is driven heavily by fluid overload between sessions, and the dialysis process itself causes rapid fluid and electrolyte shifts. Drug selection has to account for whether a medication is removed during dialysis. ACE inhibitors like lisinopril are cleared by dialysis, which means their blood-pressure-lowering effect weakens during and immediately after a session. ARBs, by contrast, are not significantly removed by dialysis and provide more consistent coverage. For patients who struggle to take daily pills, renally eliminated agents like lisinopril or atenolol can be given three times a week right after dialysis sessions.20PubMed Central. Antihypertensive agents in hemodialysis patients: a current perspective
Calcium channel blockers are not removed by dialysis either, making them a practical second-line option for dialysis patients who need additional blood pressure control. Beta-blockers are a mixed bag: some are dialyzable, some are not, and they vary in how selective they are for the heart versus other tissues, making a single recommendation difficult.21PubMed Central. A Comprehensive Review on the Efficacy of Antihypertensives in Patients With End-Stage Renal Disease In dialysis, getting fluid balance right through adequate ultrafiltration and sodium restriction often matters more than any specific drug choice.
Beta-Blockers and Resistant Hypertension
Beta-blockers are not kidney-protective drugs in the way that ACE inhibitors or SGLT2 inhibitors are. They do not reduce glomerular pressure or proteinuria. But they have a role in CKD patients whose blood pressure remains uncontrolled despite a RAAS blocker, an SGLT2 inhibitor, and a diuretic, especially if the resting heart rate is elevated. Expert opinion suggests that a heart rate above about 80 beats per minute in a hypertensive patient is associated with higher mortality, and adding a beta-blocker may be reasonable in that setting.22American Journal of Kidney Diseases. Management of Resistant Hypertension in Chronic Kidney Disease: Core Curriculum 2020
For truly resistant hypertension in advanced CKD, where four or more drugs are already on board and blood pressure remains above goal, the options get thin. Centrally acting agents like clonidine or methyldopa can be added and are relatively safe in CKD, though no large trial has shown they slow kidney disease or reduce cardiovascular events in this population.23Vascular Health and Risk Management. How Do I Manage Hypertension in Patients with Advanced Chronic Kidney Disease Not on Dialysis? Perspectives from Clinical Practice At that point, the goal is pragmatic: whatever lowers the blood pressure and the patient can tolerate.
Does It Matter When You Take the Pill?
The idea of taking at least one blood pressure medicine at bedtime instead of in the morning, sometimes called chronotherapy, has been debated for years. In CKD, it may carry particular relevance because many patients lose the normal nighttime dip in blood pressure, and elevated nighttime pressure appears to be especially harmful to the kidneys. A study testing a combination of an ARB (olmesartan) and a calcium channel blocker (amlodipine) found that bedtime dosing improved nocturnal blood pressure control more than morning dosing, without weakening the daytime effect. The mechanism may involve the drug catching the nighttime spike in renin-angiotensin activity and the pharmacokinetics of amlodipine, which reaches its peak concentration 6 to 12 hours after a dose and is absorbed more completely when taken at night.24PubMed Central. Morning vs Bedtime Dosing and Nocturnal Blood Pressure Reduction in Patients With Hypertension
This is not settled science, and larger trials have been less enthusiastic about bedtime dosing as a universal strategy. But for CKD patients who are confirmed non-dippers on 24-hour monitoring, shifting one drug to bedtime is a low-risk adjustment worth discussing. It costs nothing extra and does not add a new medication or new side effects.
Racial Disparities in Kidney Disease and Drug Response
Black patients face a disproportionately high burden of CKD and tend to progress to kidney failure faster than non-Black patients with similar blood pressure levels. The reasons are a tangled mix of genetic susceptibility, including variants in genes like APOL1 that strongly influence kidney risk, along with socioeconomic and healthcare-access disparities.25Kidney International. Renal outcomes in hypertensive Black patients at high cardiovascular risk From a drug-choice standpoint, older guidelines often recommended calcium channel blockers or diuretics as first-line for Black patients with uncomplicated hypertension, because ACE inhibitors and ARBs tend to produce a smaller blood pressure drop in Black patients on average. But when significant proteinuria or CKD is present, the kidney-protective effects of RAAS blockers outweigh the slightly smaller blood pressure reduction. In that setting, an ACE inhibitor or ARB should still be the foundation, often combined with a diuretic to enhance the blood pressure effect.
SGLT2 inhibitors and finerenone have shown kidney benefits across racial subgroups in their major trials, though the populations studied were not always large enough for definitive subgroup conclusions. For any patient, regardless of background, the principle is the same: proteinuria-lowering and glomerular-pressure-lowering drugs form the first tier, and blood-pressure-lowering drugs that lack those properties fill in afterward as needed.